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Abstract
Background: TK2 gene encodes for mitochondrial thymidine kinase, which phosphorylates the pyrimidine
nucleosides thymidine and deoxycytidine. Recessive mutations in the TK2 gene are responsible for the ‘myopathic
form’ of the mitochondrial depletion/multiple deletions syndrome, with a wide spectrum of severity.
Methods: We describe 18 patients with mitochondrial myopathy due to mutations in the TK2 gene with absence
of clinical symptoms until the age of 12.
Results: The mean age of onset was 31 years. The first symptom was muscle limb weakness in 10/18, eyelid ptosis
in 6/18, and respiratory insufficiency in 2/18. All patients developed variable muscle weakness during the evolution
of the disease. Half of patients presented difficulty in swallowing. All patients showed evidence of respiratory
muscle weakness, with need for non-invasive Mechanical Ventilation in 12/18. Four patients had deceased, all of
them due to respiratory insufficiency. We identified common radiological features in muscle magnetic resonance,
where the most severely affected muscles were the gluteus maximus, semitendinosus and sartorius. On muscle
biopsies typical signs of mitochondrial dysfunction were associated with dystrophic changes. All mutations
identified were previously reported, being the most frequent the in-frame deletion p.Lys202del. All cases showed
multiple mtDNA deletions but mtDNA depletion was present only in two patients.
Conclusions: The late-onset is the less frequent form of presentation of the TK2 deficiency and its natural history is
not well known. Patients with late onset TK2 deficiency have a consistent and recognizable clinical phenotype and
a poor prognosis, due to the high risk of early and progressive respiratory insufficiency.
Keywords: TK2 deficiency, Mitochondrial myopathy, Multiple deletions
Background
Defects in the maintenance and repair of mitochondrial
DNA (mtDNA) result in an emerging and heterogeneous
group of mitochondrial disorders, caused by alterations of
the nuclear genes involved in mtDNA replication [1–3].
This group includes defects in enzymes involved in the
maintenance of the balanced pool of deoxynucleotides of
the mitochondria, which are crucial in the biosynthesis of
the mitochondrial genome and have therapeutic implica-
tions [4, 5]. The disrupted synthesis of mtDNA results in
qualitative (multiple deletions) and/or quantitative (a drastic
decrease in the number of copies or depletion) defects of
the mtDNA. In particular, one of the ‘myopathic forms’ of
the mitochondrial depletion/multiple deletions syndromes is
caused by mutations in the TK2 gene which encodes for
mitochondrial thymidine kinase, which phosphorylates the
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pyrimidine nucleosides thymidine (dT) and deoxycytidine
(dC) [1, 6].
Recessive mutations in the TK2 gene (MIM# 609560) are
responsible for diverse clinical presentations mainly charac-
terized by progressive muscle weakness, dysphagia and re-
spiratory involvement with a wide spectrum severity and of
age of onset. TK2 deficiency was initially described by Saada,
et al. in 2001 [6] in four children with a severe myopathy as-
sociated with depletion of the mtDNA. Since then, a number
of cases have been reported depicting a heterogeneous clin-
ical presentation with a continuum spectrum of the disease,
which includes early-onset extremely severe and rapidly pro-
gressive forms with survival of less than two years, to less se-
vere forms with late or very late onset, and a variably slower
rate of progression [7, 8]. In 2012, Tyynismaa, et al. reported
the first two cases with mutations in theTK2 gene with onset
in the fifth decade of life, manifesting chronic progressive ex-
ternal ophthalmoplegia (CPEO) associated with limb muscle
weakness and dysphagia [9]. A recent publication that in-
cluded 92 patients describing the natural history of this dis-
order proposed the classification of three clinical forms
according to ages-at-onset: infantile (< 1 year-old), childhood
(1–12) and late (> 12 years) onset. Nearly 40% of the reported
TK2 cases presented with the symptoms prior to the age of
1, in another 41% the onset occurred between the ages of
one and 12, and only in 19% of patients did the symptoms
appeared after the age of 12 [7]. A subsequent retrospective
review, with similar frequencies for those three subgroups,
included eleven new cases of which only three were classified
as late-onset [8]. So far, the natural history of patients with
late onset TK2 deficiency has not been defined in detail.
Here, we report on the clinical features and assess-
ments in a large series of 18 patients with late-onset
TK2 deficiency, the less known and poorest defined
form of this disease, to further characterize this patient
subgroup. Expanding the natural history and prognosis
of late-onset TK2 deficiency will facilitate earlier diagno-
sis and identification for treatment with therapies under
clinical development.
Methods
Patients
We describe the phenotypic features of 16 Spanish and 2
US patients with mitochondrial myopathy due to muta-
tions in the TK2 gene with the absence of clinical symp-
toms until the age of 12. The series include three pairs
of siblings (P3-P4, P6-P10 and P14-P15). Partial data
from five patients have been previously published else-
where (P1, P5, P9 [7], P3 and P12 [10]).
Clinical evaluation
The electronic records were reviewed to collect informa-
tion about the age of onset, initial symptoms, severity,
distribution and progression of the muscle weakness and
extra-muscular symptoms. We gathered information
from the latest neurological examination registered in-
cluding, when available, the Muscle Research Council
(MRC) scale to assess the muscle strength and the 6 min
walk test (6MWT) for functional evaluation.
Respiratory assessment
The latest value of the forced vital capacity (FVC) in
seated and supine position, maximum inspiratory pres-
sure (MIP), blood gas analysis, nocturnal ventilation
(assessed with nocturnal pulse oximetry and/or capno-
graphy [11] and the need for mechanical ventilation
(MV) type and hours of use were recorded.
Laboratory tests
CK (creatine kinase) and lactate levels were quantified in
serum in basal conditions, at diagnosis. GDF-15
(growth/differentiation factor-15) levels were quantified
in plasma samples using human GDF-15 quantitative
ELISA kit (R&D Biosystems) according to the manufac-
turer’s instructions.
Muscle MRI
Muscle MRI was performed in 8 of the 18 patients. All
of them were scanned in a 1.5 T MR scanner (Siemens).
Lower limb axial T1-weighted sequences were used for
morphological analysis and short-tau inversion recovery
(STIR) sequences were examined to detect muscle
edema. The muscle MRI studies were evaluated by the
same neurologist (R F-T) with wide experience in neuro-
muscular disorders. The evaluator was blind regarding
the clinical manifestations. He scored pelvic, thigh and
lower leg muscles in axial T1-sequences with the semi-
quantitative Mercuri visual scale (MVS) modified by
Fisher [12]: 0: Normal appearance; 1: Mild involvement,
less than 30% of individual muscle volume; 2: Moderate
involvement, 30–60% of individual muscle volumes; 3:
Severe involvement, > 60% of individual muscle; 4: End
stage, all the muscle is severely affected, replaced by in-
creased density of connective tissue and fat, with only a
rim of fascia and neurovascular structures distinguish-
able. We compared median value of muscle fatty re-
placement using the Wilcoxon-Mann-Whitney test.
Statistical analyses were performed using IBM SPSS Sta-
tistics, V.22 (IBM, Armonk, New York, USA).
Aerobic exercise testing
Exercise testing was performed in 5 patients on a cycle
ergometer, following a ramp-like protocol (workload in-
creases of 1W every 6 s [averaging 10W·min− 1] starting
from an initial load of 0W, with a pedal cadence of 60–
70 rpm throughout the test). Gas-exchange variables
were collected breath-by-breath with an automated
metabolic cart (Quark CPET, COSMED, Rome, Italy).
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The peak oxygen uptake (VO2 peak) was computed as
the highest value obtained for any 10-s period during
the tests [13].
Muscle biopsy
Muscle samples were obtained by open biopsy and proc-
essed following the standard procedures: Hematoxylin
and eosin (H&E), modified Gomori trichrome, ATPase
(adenosine triphosphatase), NADH (nicotinamide adenine
dehydrogenase), SDH (succinate dehydrogenase), COX
(cytochrome C oxidase), and COX-SDH stains were per-
formed in all available samples. Respiratory chain enzyme
activity levels were recorded when available.
Genetic studies
Molecular diagnosis was performed either by direct
Sanger sequencing of exons and intron/exon boundaries
of the TK2 gene, or by customized next generation
sequencing (NGS) panels. Patient’s skeletal muscle
mtDNA deletions were investigated by long-range PCR
(polymerase chain reaction) and/or Southern blot, and
mtDNA copy number was assessed by quantitative PCR
as previously described [10, 14].
The study was approved by the institutional review
board of every centre and all patients signed an informed
consent for the anonymous publication of this data.
Results
Clinical manifestations (Table 1)
We included 18 patients (6 male, 12 female). The mean
age-at-onset was 31 years (range 12 to 60 years) with a
mean age at diagnosis of 48.5 years (range 23 to 73 years)
resulting in an average of 17.4 years between the onset
of the disease until reaching a genetic diagnosis (range 1
to 44 years). The mean duration of the disease was 19.8
years (range 6 to 44 years). Four patients from the series
were deceased, all of them due to respiratory insuffi-
ciency a mean of two decades after the onset.
The first symptom was muscle limb weakness in 10/18
(55.6%), eyelid ptosis in 6/18 (33%) (two patients also
presented ophthalmoparesis), and respiratory insuffi-
ciency in 2/18 (11.1%). All patients developed muscle
weakness during the evolution of the disease, 17/18
showing proximal and distal limb muscle weakness, 1/18
with only distal limb weakness, and 16/18 axial involve-
ment. It is noteworthy that neck flexor weakness was
clearly more severe than limb weakness (mean, 2.14 on
the MRC scale).
The following muscle groups were the most frequently
affected, in a symmetrical manner: shoulder abductor
(mean, 4 on the MRC scale), hip flexor (mean, 3.75 on
the MRC scale) and hip extensor (mean, 3.87 for both
on the MRC scale) and finger extensor muscles (mean,
4.14 on the MRC scale). Four patients (22%) lost the
ability to walk without support. Facial musculature was
symmetrically affected in 17 patients (94.4%), with pre-
dominance of the orbicular oculis muscle. 16/18 of the pa-
tients (88.9%) also had symmetrical eyelid ptosis of
variable severity, with this being the first symptom in 6 pa-
tients (33.3%). Six of them required surgical blepharo-
plasty due to vision impairment. Nine patients had CPEO.
The majority (11/18) had difficulty in swallowing,
which resulted in severe weight loss and/or detriment to
the safety of oral feeding in 6 cases, requiring percutan-
eous gastrostomy tube in 5 cases (27.8%) on average
19.6 years after the onset of the disease (ranging from 12
to 28 years).
Other clinical manifestations included sensory axonal
polyneuropathy (7/18;38.9%), neurosensory hearing loss
(3/18;16.6%) and dysphonia due to vocal cord palsy (2/
18;11.1%). No patient had cardiomyopathy.
Respiratory function
FVC at diagnosis from the total cohort was 55.4% (ranging
from 17 to 103) with a mean decrease of FVC in supine
position of 8% (ranging from 0 to 14), and a mean MIP of
36.8% (ranging from 20 to 101%), independent of the asso-
ciated muscle symptoms. From a respiratory perspective,
the high frequency of complications should be noted, with
need for non-invasive MV in 12/18 patients (66.6%). The
mean use of the MV was 11.6 h per day (ranging from 8 to
24 h). Eight out of the 12 patients with MV (66.6%) pre-
sented with acute respiratory insufficiency following a rou-
tine upper respiratory infection as the first manifestation of
the disease. None of these cases had any prior respiratory
symptoms; however, once detected, they required MV due
to hypercapnia secondary to alveolar hypoventilation. Al-
though limb muscle weakness and/or eyelid ptosis were
already present at the onset of respiratory insufficiency,
those neuromuscular symptoms had not prompted a neur-
ology consultation in any of the eight patients. Thus, the re-
spiratory involvement resulted in the diagnosis of an
underlying myopathy in these patients; the mean FVC was
of 40.8% (range from 28 to 58) at the time of diagnosis. Of
the six patients who did not needed MV, all showed evi-
dence of respiratory muscle weakness on functional tests,
although only one of them (P8) reported respiratory symp-
toms (orthopnoea), suggesting diaphragmatic weakness.
This patient displayed ptosis and CPEO at the age of 50 as-
sociated with moderate axial and proximal limb muscle
weakness (4 on the MRC scale). Strikingly, although the
functional respiratory tests and nocturnal pulse oximetry
were normal (FVC seated 103%, FVC decubitus 100% and
MIP 101%) nocturnal transcutaneous capnography revealed
high mean levels of carbon dioxide (CO2, mean of 48
mmHg, with a maximum peak of 54mmHg).
Four patients died of respiratory insufficiency at mean
age of 56 years (ranging from 40 to 68), and a mean of
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24 years after the onset of their initial symptoms (ran-
ging from 17 to 35).
CK and lactate levels (Table 2)
94.4% of patients had increased variable serum CK levels
ranging from 190 to 2435 UI/l (normal levels < 170 UI/
l)), and 16.7% showed levels 10-fold above the upper
normal limit. Serum lactate levels were measured in
basal conditions in 12 of the 18 cases. Of these, only
three (25%) displayed slightly increased levels (1.4-2x
above the upper normal limit).
GDF-15 levels
GDF-15, a biomarker identified in the analysis of transcrip-
tomic profiling of TK2 deficient human skeletal muscle [15],
has been proven useful in the diagnosis of mitochondrial
myopathies [16], being especially increased in patients with
mitochondrial TK2 deficiency [17]. Serum levels of GDF-15
were increased in 5 out of 5 cases analysed (100%), ranging
from 1529 to 2438 pg/mL (2113 pg/mL ± 462, mean ±
standard deviation, upper limit of normal =550 pg/mL) [16].
Muscle MRI findings
It was performed in 8 patients. Mean age at muscle MRI
was 46.4 years old (range: 23–73). Mean disease duration
at the time of the scan was 18 years (range 10–31). The
most severely affected muscles in axial T1-weighted se-
quences were the gluteus maximus, semitendinosus, sar-
torius and gastrocnemius medialis (median MVS: 3). Of
these, only the gluteus maximus and sartorius were af-
fected in all patients. Apart from the later, gluteus med-
ius, adductor magnus and semitendinosus were also
moderately affected in the thighs and gastrocnemius
lateralis in the legs (median MVS: 2). No muscle fat in-
filtration was observed in obturator, quadratus femoris,
extensoris digitorum and tibialis posterior (Fig. 1). The
Table 2 Biochemical and molecular characteristics
ID Mutation Muscle
Biopsy
Multiple
Deletions
Residual
mtDNA (%)
Respiratory Chain
Enzyme Activity
CK
(UI/l)
GDF-15
(pg/mL)
Lactate
(mmol/l)Allele 1 Allele 2
1 c.323C > T (p.Thr108Met) c.323C > T (p.Thr108Met) Yes Yes 17 CI, CIII and CIV
deficit
2435 2423 1.95
2 c.323C > T (p.Thr108Met) c.323C > T (p.Thr108Met) Yes Yes 39 Normal 303 2439 2.3
3 c.604–606 AAGdel (p.Lys202del) c.604–606 AAGdel
(p.Lys202del)
Yes Yes 60 CIII deficit 294 1695 2.6
4 c.604–606 AAGdel (p.Lys202del) c.604–606 AAGdel
(p.Lys202del)
ND ND NA ND 647 2483 2.2
5 c.604–606 AAGdel (p.Lys202del) c.604–606 AAGdel
(p.Lys202del)
Yes Yes 66 Normal 357 1529 1.5
6 c.323C > T (p.Thr108Met) c.323C > T (p.Thr108Met) Yes Yes 19 Normal 425 NA 1.6
7 c.604–606 AAGdel (p.Lys202del) c.604–606 AAGdel
(p.Lys202del)
Yes Yes 33 NA 568 NA 2.6
8 c.604–606 AAGdel (p.Lys202del) c.604–606 AAGdel
(p.Lys202del)
Yes Yes NA NA 405 NA 2.4
9 c.323C > T (p.Thr108Met) c.323C > T (p.Thr108Met) Yes Yes 35 CI, CIII and CIV
deficit
190 NA NA
10 c.323C > T (p.Thr108Met) c.323C > T (p.Thr108Met) Yes NA NA Normal 405 NA 3
11 c.604–606 AAGdel (p.Lys202del) c.604–606 AAGdel
(p.Lys202del)
Yes Yes NA ND 266 NA NA
12 c.604–606 AAGdel (p.Lys202del) c.604–606 AAGdel
(p.Lys202del)
Yes Yes NA ND 350 NA NA
13 c.388C > T (p.Arg130Trp) c.415G > A (p.Ala139Thr) Yes Yes NA CI, CIII and CIV
deficit
170 NA 4.14
14 c.623A > G (p.Tyr208Cys) c.623A > G (p.Tyr208Cys) Yes Yes NA CI, CIII and CIV
deficit
1739 NA NA
15 c.623A > G (p.Tyr208Cys) c.623A > G (p.Tyr208Cys) ND NA NA ND 381 NA NA
16 c.323C > T (p.Thr108Met) c.323C > T (p.Thr108Met) Yes Yes 53 Normal 233 NA 1.77
17 c.469_470insTGGG
(p.Asp157Valfs*11)
c.156 + 6 T > G Yes Yes 50 NA 537 NA NA
18 c.604–606 AAGdel (p.Lys202del) c.604–606 AAGdel
(p.Lys202del)
NA NA NA NA 1348 NA NA
NA not available, ND not done, CK creatine kinase, GDF-15 Growth differentiation factor-15
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Fig. 1 Axial T1 muscle MRI and bar charts with Mercuri Visual Scale (MVS) distribution for 7 patients and per anatomical region. a, Axial T1 muscle
MRI in pelvis: These two consecutive slices from different patients are showing that the gluteus maximus (marked with asterisk) is the most
affected muscle. Tensor fascia latae is affected while obturator and quatratus femoris are less affected. b, Bar chart MVS fat replacement in pelvis:
MVS (0: no fat replacement, 4: the muscle is completely replaced) for all patients. Gluteus maximus is the most affected muscle, followed by
tensor fascia latae. c, Axial T1 muscle MRI in thighs: These two slices from two different patients are showing the fat replacement of sartorius
(wide white arrow) and vastus lateralis (thin white arrow). Other muscles like semitendinosus, semimembranosus and gracilis are also moderately
affected. d, Bar chart MVS fat replacement in thighs: MVS for all patients. Sartorius, semimembranosus, semitendinosus, gracilis and vastus lateralis
are the most affected muscles. Sartorius and gracilis are affected in all patients. e, Axial T1 muscle MRI in legs: These two slices from two different
patients are showing the fat replacement of gastrocnemius medialis (white arrow head). Gastrocnemius lateralis and soleus are also moderately
affected. Tibialis anterior and tibialis posterior are the least affected. f, Bar chart MVS fat replacement in legs: MVS for all patients. Gastrocnemius
medialis and lateralis are the most affected muscles in legs. Tibialis anterior, extensoris digitorum and tibialis posterior are the least
affected muscles
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fat replacement followed a diffuse pattern and no focal
areas of fat infiltration were detected. We did not ob-
serve statistical differences regarding asymmetric in-
volvement. STIR sequence was normal in all patients.
Aerobic exercise testing
In addition to weakness, one of the most frequent clin-
ical manifestations in the mitochondrial myopathies is
poor exercise capacity [18].The latter is reflected by low
levels of VO2peak or by poor muscle-oxygen extraction
(as assessed with near-infrared spectroscopy) during
graded cycle-ergometer/treadmill testing [19]. Aerobic
exercise testing was performed on a cycle ergometer in
five patients. The mean ± SD VO2 peak obtained was
14.8 ± 3.2 mL/kg− 1/min− 1, with normal consumption
values of 40.0 ± 9.5 mL/kg− 1/min− 1 [20].
Muscle biopsies
Muscle biopsies were performed in 16 patients, 11 were
available to re-analysis. The morphological study re-
vealed numerous ragged-red fibers in 100% of the biop-
sies, which were hyper-reactive with SDH reaction and
usually COX-deficient. COX-deficient fibers accounted
for approximately 5–15% of all fibers. Frequently these
muscles also showed dystrophic features with frequent
necrotic fibers, some with phagocytosis, and increased
endomysial connective tissue (present in 7 out of 11 bi-
opsies revised). Marked type I fiber predominance was
also observed in 2 patients (Fig. 2). These findings differ
from the usual pattern displayed in other mitochondrial
myopathies, where the typical signs of mitochondrial
proliferation and dysfunction are not associated with
other relevant changes in muscle histology structure
[21]. We have results of the analysis of the enzymatic ac-
tivity of respiratory chain complexes of 10 patients. Only
in half of them a reduction in the activity of one or more
enzymatic complexes were identified (Table 2).
Genetic studies
All patients harbored biallelic mutations in the TK2
gene (Ref.Seq. NM_004614.4) (Table 2). Most patients
(16/18;88.9%) were homozygous. All mutations were
previously reported [7, 8], with the in-frame deletion
p.Lys202del (c.604_606AAGdel) being the most fre-
quent (16/36 alleles; 44.4%), followed by the missense
mutation p.Thr108Met (c.323C > T) (12/36;27.8%).
Additionally, three missense mutations were identified
in 3 patients: p.Arg130Trp (c.388C > T), p.Ala139Thr
(c.415G > A), and p.Tyr208Cys (c.623A > G). Finally,
one patient harbored a frameshift mutation p.Asp157
Valfs*11(c.469-470insTGGG) in compound heterozy-
gosis with a splice site mutation c.156 + 6 T > G.
Genetic data from patients P1, P2, P5, P9 and P12,
were previously reported [7, 10]. Muscle mtDNA
copy-number was studied in 9 patients and severe
mtDNA depletion was detected in only two (17% of
residual mtDNA in P1 and 19% of residual mtDNA
in P6). Fourteen out of 14 patients (100%) showed
the presence of multiple mtDNA deletions in muscle.
Discussion
The late-onset presentation of TK2 deficiency is the least
frequent clinical mode of presentation known. These pa-
tients are considered to have a milder presentation than
those with infancy and childhood onset disease, however,
few cases have been described to date and those re-
ported were not extensively explored. So far, 17 patients
with late-onset were reported to harbour TK2 biallelic
mutations [7–10, 22]. However clinical details were
scarce, heterogeneous, and reports did not clearly define
the phenotype or rate of progression of the disease. In
some cases, clinical presentation is similar to that de-
scribed in the childhood onset patients, with progressive
limb, facial, extraocular, oropharyngeal and respiratory
muscle weakness, but with a slower progression, whereas
in other cases, CPEO is the main manifestation [9]. Re-
spiratory insufficiency has been mentioned as a potential
cause of death although comprehensive data about the
respiratory involvement is not available for all the previ-
ously published patients: severe respiratory insufficiency
is described in 41% of the reported cases but in the
remaining 59% this data is unavailable or superficially
described [7, 8, 22].
We identified 16 Spanish and two North American pa-
tients, from 13 different families, with TK2 mutations and
a late-onset presentation. Exhaustive clinical description is
here provided to facilitate earlier and accurate diagnosis
and to improve the knowledge of the natural history of
this rare, and probably underdiagnosed disorder.
The clinical features and results of the diagnostic tests
described in our series show a homogeneous phenotypic
pattern in late-onset TK2 deficiency consisting of pro-
gressive proximal limb, axial neck flexor and facial
muscle weakness frequently associated with ptosis,
ophthalmoparesis and bulbar weakness, along with an
early and severe, although unrecognized, respiratory in-
volvement. Diaphragmatic weakness is very characteris-
tic, occurring in all of our cases, showing an early onset
but slow progression; 12/18 (66.6%) required MV during
the evolution of the disease and in 8/18 (44.4%) was the
cause for the first medical consultation. This pattern of
respiratory involvement was found even in patients who
only had an apparently isolated CPEO phenotype.
Therefore, it is critical to identify signs of nocturnal
hypoventilation during clinical evaluation of these pa-
tients, regardless of the severity of the skeletal myopathy.
This discrepancy between diaphragmatic and limb weak-
ness was also reflected in some patients with virtually
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normal 6MWT results, despite using MV (see Table 1).
In our series, the capnography was the most sensitive
test for detecting the respiratory dysfunction, since it
was abnormal even before basal FVC and MIP revealed
alterations.
Muscle biopsies showed the typical findings of mito-
chondrial dysfunction described in most mitochondrial
myopathies. However, as in other TK2 deficiency forms,
they also revealed dystrophic features which are distinct
from the majority of other mitochondrial myopathies.
Thus, our data support that the association of both
mitochondrial and dystrophic pattern strongly suggest
mutations in the TK2 gene as the underlying cause.
All previously published late-onset patients showed
multiple mtDNA deletions, while mtDNA depletion was
found only in one of the five cases in whom the mtDNA
copy-number was quantified. Our findings corroborate
the previous results indicating the presence of multiple
mtDNA deletions is more frequent than mtDNA deple-
tion in the late-onset TK2 deficient patients. Previous re-
ports showed that mtDNA depletion is found in the
most of early onset patients [7], but our data support
that it cannot be considered a valid prognostic marker
since it can also be found in late-onset cases.
In muscle MRI the fat muscle replacement was diffuse,
resembling many muscular dystrophies and congenital
myopathies. Muscle degeneration in MRI was described
in five MERRF patients with the m.8344A > G mutation
[23], and more recently fatty infiltration has been com-
municated in patients with single, large-scale deletions
of mitochondrial DNA [24]. However, no extensive stud-
ies have been published trying to define muscle MRI
patterns in different mitochondrial myopathies. So, there
is no specific MRI pattern for any mitochondrial myop-
athy described so far. In our series of TK2 patients al-
though no clear pattern of fat infiltration was detected,
we have identified some radiological common features,
as the involvement of the sartorius muscle in all cases.
This muscle is usually spared until late stages in many
genetic muscle diseases (is only affected early in some
myofibrillar myopathies, in the Laing distal myopathy
and in RYR1-related myopathies (encodes for ryanodine
receptor 1 protein) [12, 25–27]), so this finding could be
helpful for differential diagnosis.
Serum GDF-15 levels have recently been revealed as a
sensitive and specific biomarker for the diagnosis of
mitochondrial myopathies [16, 17]. In our series, it
proved to be very high in all analysed cases, so it could
orientate the molecular diagnosis in a proper clinical
context, before the muscle biopsy was performed.
As in other mitochondrial myopathies [19], in our
series the cardiopulmonary exercise testing identified a
Fig. 2 Morphological alterations in muscle biopsies from patients P1 (a, f, k, p), P5 (b, g, l, q), P9 (c, h, m, r), P14 (D, i, n, s) and P16 (e, j, o, t). a-e
H&E shows dystrophic features in all cases with mild endomysal fibrosis, adipose tissue replacement, atrophy and necrotic fibers. Ragged-red
fibers are frequently identified in all muscle samples (arrows). f-j Gomori trichrome showed the characteristic ragged-red fibers in all the biopsies.
k-o Succinate dehydrogenase (SDH) reveals an increase of the oxidative staining in numerous fibers. p-t Frequent cytochrome C oxidase (COX)
deficient fibers are present in variable proportion in the different cases (p and r, COX staining; o, s and t, COX-SDH combined staining). Scale
bar =100 μm
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very reduced consumption of oxygen, even in patients
with CPEO as a predominant clinical manifestation
(P8). This indicates that, although the weakness may
not be severe in late-onset TK2 deficiency patients,
the exercise capacity is abnormally low, ultimately
impairing physical activity.
Noticeably, the p.Lys202del was the most frequent
mutation in the TK2 gene in our series of late-onset pa-
tients, which is consistent with the finding that this mu-
tation appears to be restricted to adult-onset cases, since
it has not been reported in any infantile-onset patients
who have not even harbouring this mutation in a single
allele [8]. Nevertheless, it was reported in one patient
with childhood-onset, who was compound heterozygous
for this mutation and a frameshift mutation, and began
showing symptoms at 2.5 years but survived until 8.5
years-old [28]. The eight cases with this mutation in our
series were all homozygous supporting the idea that this
mutation is associated with a milder effect (age at onset
ranging from 25 to 60 years). Interestingly, this mutation
has only been identified in 13 unrelated Spanish patients
((11, 13, 26, 27, and this study), 2 related patients from
Hispanic ethnic background [10], and one patient from
Venezuela (this study) suggesting that it could be a pri-
vate mutation and that Spanish/Hispanic candidate pa-
tients may be amenable for a rapid genetic screening of
this mutation. However, haplotype analysis would be re-
quired to confirm the possible founder effect of this mu-
tation. The p.Thr108Met mutation was the second most
common mutation in this study, however it has been
found in infantile and childhood onset cases [6, 7] of dif-
ferent geographic origin.
TK2 deficiency is a severe disorder causing premature
death. In recent pre-clinical studies, it has been demon-
strated that treatment with pyrimidine nucleosides (dC
+ dT) in the H126N knock-in mouse model of TK2 defi-
ciency, leads to a prolonged life span in the animals and
a restored mtDNA copy number, without significant tox-
icity [4]. This opens the door to a potential therapeutic
intervention in humans with this metabolic hereditary
disorder, making it necessary to define sensitive and ob-
jective outcomes to assess an eventual response to treat-
ment. Our findings suggest that functional respiratory
tests, serum GDF-15 level and the stress cyclometer
evaluation are potentially good candidates for monitor-
ing the progression of disease.
Conclusion
In summary, our study shows that late-onset patients with
mitochondrial TK2 deficiency have a consistent and
recognizable clinical phenotype, characterized by a pro-
gressive myopathy with predominant facial and axial neck
flexor weakness, and respiratory involvement, often asso-
ciated to CPEO. Their prognosis is poor, due to the high
risk of early and progressive respiratory insufficiency. Yet,
some patients may present with a severe acute respiratory
failure. Early detection of respiratory involvement requires
an active search in the clinics, even in asymptomatic pa-
tients. A small number of rationally designed treatments
are being developed for mitochondrial disorders [29], in-
cluding nucleoside substrate enhancement therapy de-
signed specifically for TK2 deficiency [4]. Therefore, early
diagnosis of TK2 deficiency is important as patients could
benefit from the existence of a potential therapy.
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